2. Academic Validation
  3. Oridonin inhibits aberrant AKT activation in breast cancer

Oridonin inhibits aberrant AKT activation in breast cancer

  • Oncotarget. 2018 Feb 1;9(35):23878-23889. doi: 10.18632/oncotarget.24378.
Bowen Sun 1 2,  Geng Wang 2 3,  Huidong Liu 2 3,  Pian Liu 4,  Waleed O Twal 5,  Hiuwing Cheung 2,  Steven L Carroll 2,  Stephen P Ethier 2,  Emily E Mevers 6,  Jon Clardy 6,  Thomas Roberts 6 7,  Changbin Chen 8,  Qian Li 8,  Lanfeng Wang 8,  Meixiang Yang 1,  Jean J Zhao 6 7,  Qi Wang 2
Affiliations

Affiliations

  • 1 The first Affiliate Hospital, Biomedical Translational Research Institute, Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou 510632, China.
  • 2 Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
  • 3 Department of Anatomy, Harbin Medical University, Harbin 150081, China.
  • 4 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
  • 5 Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
  • 6 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
  • 7 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • 8 Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
PMID: 29844859 DOI: 10.18632/oncotarget.24378
Abstract

Aberrant activation of phosphatidylinosito-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/Akt) signaling in Cancer has led to pursuit of inhibitors for targeting this pathway. However, inhibitors of PI3K and Akt have failed to yield efficacious results without adverse effects. Here, we screened a library containing 441 authenticated traditional chinese medicine (TCM) plant extracts by examining their effect on cell viability of a human mammary epithelial cell line HMEC-PIK3CAH1047R, which expresses mutant PIK3CAH1047R and has constitutively active Akt signaling. We found that Oridonin, an extract from Rabdosia rubescens, reduced cell viability to the greatest extent. Oridonin binds to Akt1 and potentially functions as an ATP-competitive Akt Inhibitor. Importantly, Oridonin selectively impaired tumor growth of human breast Cancer cells with hyperactivation of PI3K/Akt signaling. Moreover, Oridonin prevented the initiation of mouse mammary tumors driven by PIK3CAH1047R. Our results suggest that Oridonin may serve as a potent and durable therapeutic agent for the treatment of breast cancers with hyperactivation of PI3K/Akt signaling.

Keywords

PI3K/AKT signaling; TCM plant extracts; mammary tumor prevention; oridonin; tumorigenesis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z